

Treatments Highlighted in **Red text** require Blueteq Authorisation

Treatments Highlighted in **Green text** also require EAMS Registration

Metastatic or Locally Advanced Inoperable Breast Cancer
(either ER +ve but hormone refractory, or ER +ve with rapidly progressive visceral disease, or ER -ve)

Tripple Negative Breast Cancer

Metastatic or Locally Advanced Inoperable Breast Cancer Her2 -ve and Hormone Receptor +ve

Her2 +ve

Her2 -ve

Consider **Atezolizumab** + Nab-Paclitaxel

1st Line Endocrine Therapy for Metastatic / Locally Advanced Disease?

Treated with (neo)adjuvant Trastuzumab?

Consider Performance Status, Symptoms, Response Rate, Side Effect profile & Patient Preference

Yes

No & without symptomatic visceral disease or prior exemestane

Aromatase inhibitor ± **CDK4/6 Inhibitor** (± Ovarian Suppression)

Abemaciclib + Fulvestrant

Time since (neo)adjuvant trastuzumab

≤6 months or progression on adjuvant trastuzumab

6-12 months

≥12 months

Chemotherapy + Trastuzumab

Docetaxel + Trastuzumab + **Pertuzumab***

Trastuzumab Emtansine (Kadcyla®)

Sequential Single Agent

Doublet if higher probability of response required

Vinorelbine
or
Capecitabine
or
Weekly Paclitaxel
or
Docetaxel
or
Eribulin
(3rd line and beyond)
or
Carboplatin
or
Weekly Epirubicin

Epirubicin + Cyclophosphamide
or
Docetaxel + Capecitabine
or
Vinorelbine + Capecitabine
or
Paclitaxel + Gemcitabine
or
Carboplatin + Gemcitabine
or
Carboplatin + Weekly Paclitaxel

Aromatase Inhibitor (not exemestane)

Previous AI?

Visceral Crisis or Endocrine Resistance

Consider **Everolimus** + Exemestane
Or
Consider alternate endocrine treatment dependant on previous treatments or chemotherapy